News|Articles|November 18, 2026

Ateganosine Plus Cemiplimab Shows 88% Disease Control in Third-Line NSCLC

Author(s)Jonah Feldman
Fact checked by: Sabrina Serani
Listen
0:00 / 0:00

Key Takeaways

  • Sequential ateganosine 180 mg followed by cemiplimab in 21-day cycles achieved 88% disease control in third-line advanced NSCLC across THIO-101 parts A–C.
  • Mechanistically, 6-thio-2’-deoxyguanosine incorporation into telomeres drives telomeric DNA damage, cancer cell death, and proposed cGAS/STING activation with downstream T-cell responses.
SHOW MORE

Updated THIO-101 data showed an 88% DCR with ateganosine followed by cemiplimab in third-line NSCLC after immunotherapy and chemotherapy.

Sequential treatment with the investigational telomere-targeting agent ateganosine (THIO) followed by cemiplimab (Libtayo) led to a high rate of disease control in patients with advanced non–small cell lung cancer (NSCLC) that progressed after immune checkpoint inhibitors and chemotherapy.1

Based on updated interim data, the disease control rate (DCR) was 88% (n = 38/43) in the third-line setting across parts A, B, and C of the phase 2 THIO-101 trial (NCT05208944), as of an October 1, 2026, data cutoff. Efficacy-evaluable patients were those with at least 1 tumor scan after starting treatment.

“Importantly, the part C interim efficacy results are well aligned with the outcomes observed in parts A and B, now across a substantially larger patient population,” said Vlad Vitoc, MD, founder and CEO of MAIA Biotechnology, in a news release.

Ateganosine Background and THIO-101 Study Design

Ateganosine is a modified nucleotide, 6-thio-2’-deoxyguanosine, that is incorporated into telomeres by telomerase, causing telomeric DNA damage and cancer cell death. According to MAIA, the resulting telomeric fragments activate innate immune signaling through cGAS/STING as well as adaptive T-cell responses.1

THIO-101 is a multicenter, open-label, dose-finding phase 2 trial. Part A is a safety lead-in, and part B is a randomized dose-finding study with doses of 60 mg, 180 mg, and 360 mg ateganosine per cycle.2 Its expansion cohorts enroll patients with advanced NSCLC who received checkpoint inhibitor therapy and chemotherapy and whose disease did not respond or progressed. Patients receive ateganosine at 180 mg followed by cemiplimab in 21-day cycles.1 Parts C and D, added by an amendment to the trial, specifically focus on the third-line patient population.

The trial’s primary objectives are safety and tolerability and efficacy as measured by ORR. Part C has completed enrollment at sites in Hungary, Poland, Turkey, Georgia, Romania, Taiwan, and the United States.1

Prior Ateganosine Data and Context

The FDA granted ateganosine fast track designation in July 2025 for NSCLC that progressed after checkpoint inhibitor therapy. In July 2026, MAIA reported a 90.5% DCR (n = 19/21) from part C alone, in which all patients had previously received docetaxel.3 Among 8 assessed patients treated in parts A and B, overall survival (OS) exceeded 2 years.4

MAIA contrasted the DCR with reported disease control rates of 25% to 35% for standard third-line chemotherapy and cited a 2021 meta-analysis and its own analyses to support that DCR can serve as a surrogate for OS.1 That comparison is across trials, and the release did not describe the duration of disease control. The company did not report the objective response rate or other efficacy and safety end points.

The company said further part C data could support an accelerated approval filing. The phase 3 THIO-104 trial (NCT06908304) is evaluating ateganosine in the same third-line population, with an interim survival analysis planned for 2027.

“It is encouraging to see an 88% [DCR] as the THIO-101 data continue to mature,” Vitoc said in the release.1

REFERENCES
1. MAIA Biotechnology Reports Consistent Strong Efficacy in Expanded Phase 2 THIO-101 Study in Non-Small Cell Lung Cancer. News release. MAIA Biotechnology. November 17, 2026. Accessed November 18, 2026. https://tinyurl.com/xreurh7x
2. THIO Sequenced With Cemiplimab in Advanced NSCLC. ClinicalTrials.gov. Updated May 13, 2026. Accessed July 8, 2026. https://clinicaltrials.gov/study/NCT05208944
3. MAIA Biotechnology Reports Strong Initial Efficacy Data in Third-Line Non-Small Cell Lung Cancer from Phase 2 THIO-101 Part C Expansion Trial. News release. MAIA Biotechnology. July 8, 2026. Accessed November 18, 2026. https://tinyurl.com/49cvetbw
4. MAIA Biotechnology Receives FDA Clearance to Open U.S. Enrollment in Ongoing Phase 2 THIO-101 Trial Expansion. News release. MAIA Biotechnology. June 3, 2026. Accessed November 18, 2026. https://tinyurl.com/5n92f94j

Related to this article